| Symbol | BTAI |
|---|---|
| Name | BIOXCEL THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 555 LONG WHARF DRIVE,12TH FLOOR, NEW HAVEN, Connecticut, 06511, United States |
| Telephone | +1 475 238-6837 |
| Fax | — |
| — | |
| Website | https://www.bioxceltherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701. Additional info from NASDAQ: |
(99% Neutral) BIOXCEL THERAPEUTICS, INC. (BTAI) Announces Business Combination
Read moreBioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
Read moreBioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
Read moreBioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
Read moreNew Form SCHEDULE 13G/A - BioXcel Therapeutics, Inc. <b>Filed:</b> 2026-03-30 <b>AccNo:</b> 0001441449-26-000004 <b>Size:</b> 8 KB
Read moreNew Form S-8 - BioXcel Therapeutics, Inc. <b>Filed:</b> 2026-03-27 <b>AccNo:</b> 0001104659-26-036227 <b>Size:</b> 238 KB
Read more(90% Positive) BIOXCEL THERAPEUTICS, INC. (BTAI) Provides Update on schizophrenia for neuroscience
Read moreBioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
Read moreBioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
Read moreNew Form 424B5 - BioXcel Therapeutics, Inc. <b>Filed:</b> 2026-03-11 <b>AccNo:</b> 0001104659-26-026158 <b>Size:</b> 592 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07116694 | Assessment of Acute Psychomotor Agitation Measures Associated With Schizophreni… | Phase2 | Bipolar I Disorder | Completed | 2025-06-19 | 2025-10-07 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| BXCL501 Sublingual Film | DRUG | Phase PHASE2 | Bipolar I Disorder | COMPLETED | NCT07116694 |
| Lorazepam 2 MG/ML | DRUG | Phase PHASE4 | Schizophrenia Agitation | RECRUITING | NCT06093451 |
| Sublingual film containing Igalmi | DRUG | Phase PHASE4 | Bipolar Disorder | COMPLETED | NCT06041646 |
| Lofexidine (Positive Control) | OTHER | Phase PHASE1 | Opioid Use Disorder | ACTIVE_NOT_RECRUITING | NCT05712707 |
| BXCL501 (240 micrograms) | DRUG | Phase PHASE1 | Opioid Use Disorder | ACTIVE_NOT_RECRUITING | NCT05712707 |
| BXCL501 (180 micrograms) | DRUG | Phase PHASE1 | Opioid Use Disorder | ACTIVE_NOT_RECRUITING | NCT05712707 |
| Pembrolizumab | DRUG | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05558982 |
| BXCL701 | DRUG | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05558982 |
| Matching Placebo | DRUG | Phase PHASE3 | Agitation | TERMINATED | NCT05665088 |
| BXCL501 | DRUG | Phase PHASE3 | Agitation | TERMINATED | NCT05665088 |
| BXCL501 60 Micrograms | DRUG | Phase PHASE1 | Schizophrenia | RECRUITING | NCT05025605 |
| BXCL501 120 Micrograms | DRUG | Phase PHASE1 | Schizophrenia | RECRUITING | NCT05025605 |
| BXCL501 80 Micrograms | DRUG | Phase PHASE1 | Schizophrenia | RECRUITING | NCT05025605 |
| Alcohol Cue Reactivity | BEHAVIORAL | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT04827056 |
| PTSD Reactivity Condition | BEHAVIORAL | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT04827056 |
| Ethanol Infusion | PROCEDURE | Phase PHASE1 | Alcohol Use Disorder (AUD) | COMPLETED | NCT04827056 |
| Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg | DRUG | Phase PHASE1 | Alcohol Use Disorder (AUD) | RECRUITING | NCT06335407 |
| Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg | DRUG | Phase PHASE1 | Alcohol Use Disorder (AUD) | RECRUITING | NCT06335407 |
| Placebo | OTHER | Phase PHASE1 | Opioid Use Disorder | ACTIVE_NOT_RECRUITING | NCT05712707 |
| Dexmedetomidine | DRUG | Phase PHASE4 | Schizophrenia Agitation | RECRUITING | NCT06093451 |
| Dexmedetomidine sublingual film | DRUG | Phase PHASE2 | Delirium | WITHDRAWN | NCT04382170 |
| Sublingual film containing Dexmedetomidine (BXCL501) | DRUG | Phase PHASE3 | Agitation Associated With Bipolar Disorder | COMPLETED | NCT04276883 |
| Placebo Film | DRUG | Phase PHASE1 | Schizophrenia | RECRUITING | NCT05025605 |
| Sublingual film containing dexmedetomidine (BXCL501) | DRUG | Phase PHASE3 | Agitation | COMPLETED | NCT04268303 |
| Sublingual Placebo Film | DRUG | Phase PHASE1 | Agitation,Psychomotor | COMPLETED | NCT04251910 |
| Sublingual film containing Dexmedetomidine | DRUG | Phase PHASE1 | Agitation,Psychomotor | COMPLETED | NCT04251910 |
| Talabostat Mesylate | DRUG | Phase EARLY_PHASE1 | Cancer of Pancreas | WITHDRAWN | NCT04123574 |
| Placebo film | DRUG | Phase PHASE2 | Agitation | WITHDRAWN | NCT05313386 |
| Sublingual film containing BXCL501 (Dexmedetomidine) | DRUG | Phase PHASE1 | Agitation | COMPLETED | NCT04010305 |
| BXCL701 monotherapy | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |
| BXCL701 plus Pembrolizumab | DRUG | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT03910660 |